To prevent osteoclastic resorption, we introduced another anti-cancer agent, AZD3463, that promisingly induced apoptosis by inhibiting the PI3K-Akt pathway in breast cancer (Hu et al., 2020; Ozates et al., 2021), neuroblastoma (Wang et al., 2016), glioblastoma (Asik et al., 2020; Goker Bagca et al., 2020), acute myeloid leukemia (Moharram et al., 2019), and Ewing sarcoma (Sampson et al., 2015). Here, AKT1 is linked to breast carcinoma.